Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Total Liabilities (2022 - 2026)

Compass Therapeutics' Total Liabilities history spans 5 years, with the latest figure at $18.7 million for Q1 2026.

  • On a quarterly basis, Total Liabilities fell 11.69% to $18.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $18.7 million, a 11.69% decrease, with the full-year FY2025 number at $22.8 million, up 50.28% from a year prior.
  • Total Liabilities hit $18.7 million in Q1 2026 for Compass Therapeutics, down from $22.8 million in the prior quarter.
  • Over the last five years, Total Liabilities for CMPX hit a ceiling of $23.5 million in Q2 2025 and a floor of $4.1 million in Q1 2024.
  • Historically, Total Liabilities has averaged $14.8 million across 5 years, with a median of $13.9 million in 2023.
  • Biggest five-year swings in Total Liabilities: crashed 67.88% in 2024 and later soared 418.67% in 2025.
  • Tracing CMPX's Total Liabilities over 5 years: stood at $18.0 million in 2022, then tumbled by 53.7% to $8.3 million in 2023, then soared by 81.96% to $15.2 million in 2024, then surged by 50.28% to $22.8 million in 2025, then dropped by 17.98% to $18.7 million in 2026.
  • Business Quant data shows Total Liabilities for CMPX at $18.7 million in Q1 2026, $22.8 million in Q4 2025, and $21.6 million in Q3 2025.